DDInter933 DDInter1763
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Insulin glulisine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Lipoic acid {u} (Compound) binds {v} (Gene) SLC5A6
SLC5A6 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Potassium chloride
Potassium chloride {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phentolamine
Phentolamine {u} (Compound) upregulates {v} (Gene) SATB1
SATB1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phentolamine
Phentolamine {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Insulin glulisine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Minocycline
Minocycline {u} (Compound) binds {v} (Gene) CYCS
CYCS {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid (Compound) binds SLC5A6 (Gene) and SLC5A6 (Gene) is downregulated by Temsirolimus (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Temsirolimus (Compound)
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates SMARCD2 (Gene) and SMARCD2 (Gene) is downregulated by Temsirolimus (Compound)
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Temsirolimus (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Phentolamine and Phentolamine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Temsirolimus (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) binds CYCS (Gene) and CYCS (Gene) is downregulated by Temsirolimus (Compound)